Zymeworks (ZYME) announced that the first patient has been dosed in the first-in-human Phase 1 trial to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers. “We are very pleased to have initiated the clinical evaluation of ZW171 for the treatment of patients with ovarian cancer and NSCLC, where it has the potential to be a highly effective therapy with favorable tolerability based on our preclinical research results,” said Jeff Smith, M.D., FRCP, Executive Vice President and Chief Medical Officer at Zymeworks. “Initiation of this trial marks a significant step forward in our effort to bring a potential new treatment to people living with difficult to treat cancers and highlights our goal to advance two therapeutic candidates, ZW171 and ZW191, into clinical studies in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZYME:
- Zymeworks Announces Board Changes with New Appointments
- Zymeworks to Unveil Q3 Financials and Corporate Update
- Zymeworks price target raised to $12 from $10 at H.C. Wainwright
- Zymeworks to Showcase New Cancer Treatments at Major Conference
- Zymeworks Appoints New EVP and CFO; Leadership Transition
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
